Call 1-877-744-5675

Other Resources*

IV FORMS: BESPONSA (inotuzumab ozogamicin) & MYLOTARG (gemtuzumab ozogamicin)

Please see full Prescribing Information for BESPONSA, including BOXED WARNING for hepatotoxicity, including VOD, and increased risk of post-HSCT non-relapse mortality, or visit BESPONSAhcp.com.

Please see full Prescribing Information for MYLOTARG, including BOXED WARNING for hepatotoxicity, or visit MYLOTARGhcp.com.

The information provided here is intended for informational purposes only, and is not a comprehensive description of potential coding requirements for BESPONSA and MYLOTARG. Coding and coverage policies change periodically and often without warning. The healthcare provider is solely responsible for determining coverage and reimbursement parameters and accurate and appropriate coding for treatment of his/her own patients. The information provided in this section should not be considered a guarantee of coverage or reimbursement for BESPONSA and MYLOTARG.

BACK TO TOP